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DTX on PC3 cell growth inhibition and similar results were
recorded after transfection of PC3 cells with shCYR61. In conclu-
sion, it is possible to design new molecular rationale-based ther-
apeutic strategies in androgen-independent prostate cancer.
doi:10.1016/j.ejcsup.2008.06.047
DOCETAXEL AND ZOLEDRONIC ACID COMBINATION ADMINIS-
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Background: Docetaxel (DTX) is effective in the treatment of
hormone-refractory prostate carcinoma patients (HRPC). In vitro
data suggest that zoledronic acid (ZOL) and DTX have a synergis-
tic effect on the growth inhibition of prostate cancer cells and
that such synergism is sequence-dependent. Therefore, prostate
cancer is a suitable target for a pharmacological combination
between DTX and ZOL. On the basis of these considerations, a
phase I trial on the combination of ZOL and DTX was designed
in the treatment of HRPC.
Materials: A dose-escalation of DTXwas planned in combination
withafixeddoseofZOL (2 mg),bothadministeredevery14days.The
following two different sequences of the two drugs were explored:
Sequence A: DTX at day 1 followed by ZOL at day 2. Sequence B:
ZOL at day 1 followed by DTX at day 2. The first dose level of DTX
was 30mg/m2 with a planned dose escalation of 10mg/m2 for each
level until 50 mg/m2. Serumcytokines and PBMCwere also collected
prior and after the different treatments at each cycle.
Results: Up to now, we have enrolled 22 patients. Six patients at
third level (Sequence B) were required due a case of vascular tox-
icity of grade III (deep thrombo-phlebitis). A different pattern of
circulating sangiogenic factors (interleukin 8 and 12, VEGF, PDGF),
cytokines (TNF-a, IFN-c, interleukin 6 and 4) and gamma/delta T
lymphocyte subpopulation was recorded in the two different
sequences. The study is still ongoing and further results will be
presented at GOIM meeting.
doi:10.1016/j.ejcsup.2008.06.048
INTRAVESCICAL GEMCITABINE VERSUS MITOMYCIN FOR
RECURRENT SUPERFICIAL BLADDER TUMOURS (STAGES PTA
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Background: Approximately, 30–40% of patients with a superfi-
cial bladder cancer treated with Bacille Calmette-Guerin(BCG) or
epirubicin do not respond and other 35% of initial responders
have a relapse within 5 years. We compare the therapeutic effi-
cacy and toxicity of intravescical instillations of Gemcitabine
(GEM) with mitomycin C (MMC) in patients with a recurrent
superficial bladder cancer.
Methods: Patients with a history of a recurrent Ta-T1, G1-G2
bladder transitional cell carcinoma, previously treated were
enrolled in the study. The patients received a 6-week course of
GEM instillations or 4-week course of MMC. In both arms, for the
initial responderswho remained free of recurrences, maintenance
therapy consisted of a 10 monthly treatment during the first year.
All patients were followed every 6 months by cystourethroscopy.
Results: A total of 120 patients were enrolled and randomly
assigned to either the MMC treatment arm or Gemcitabine treat-
ment arm. The remaining 109 patients (55 in MMC arm and 54 in
Gemcitabine arm) were evaluable. The median duration of follow-
up was (identical for both groups) 34 months.
Of the 54 patients in the Gemcitabine group 42(78%) remained
free of recurrence compared to 37 (67%) of the 55 patients treated
with MMC (p = 0.05). Among patients with recurrences, 10 in the
MMC arm and 6 in the Gemcitabine group had progressive disease
by stage: either local urothelial spread, or muscle infiltration, in 5
and 3, respectively. Local toxicity in both treatment groups was
acceptable. The incidence of. chemical cystitis in MMC arm was
statisticantly different from that in GEM group (p = 0,012).
Conclusions: Gemcitabine for its better clinical activity and
favourable toxicity profile than MMC, is a logical candidate for
intravescical therapy in refractory transitional cell patients. Final
results will be presented at 2008 ASCO Meeting.
doi:10.1016/j.ejcsup.2008.06.049
HIGH-DOSE CHEMOTHERAPY AS INITIAL SALVAGE TREATMENT
IN RELAPSED TESTICULAR CANCER PATIENTS
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Background: In the last few years, high dose chemotherapy
(HDCT) with haematopoietic stem cell transplantation (HSCT)
has been increasingly investigated as a therapeutic option for
early or late intensification in patients with poor prognosis germ
cell tumor (GCT) or in pats who relapse or who have a partial
response after a first line chemotherapy.
Methods: Eleven patients were treated with three cycles of VeIP
(ifosfamide 1200 mg/m2, mesna 1200 mg/m2, cisplatin 20 mg/m2,
days 1–5 and vinblastine 0.11 mg/kg, days 1–2) and one course
of HDCT: Carbo-PEC (carboplatin 400–550 mg/m2/day on day 1,
etoposide 450 mg/m2/day, cyclophosphamide 1600 mg/m2/day
and mesna 3600 mg/m2 on days 1–4) followed on day 7 by HSCT.
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The IGCCCG stage was III A in 1, III B in 3 and III C in 7. The med-
ian age was 24 years (range 17–33).
Results: Ten patients were assessable for response: 3 CR, 4 PR, 2
SD and 1 PD were observed. One patient died due to brain hemor-
rhage (on day 10 from Carbo-PEC). Four patients underwent to
surgery and two were pCRs. Six patients (54%) are still alive with
a median follow up of 100 months (range 78–148). Four patients
progressed after chemotherapy and died from disease at 5, 10,
32 and 34 months from the date of the start of the first chemo-
therapy cycle. Event free survival rates (defined as time to disease
progression, relapse or death, whatever the cause) were mea-
sured from the date of the start of the first chemotherapy cycle
at 1 and 3 years and resulted 72% and 54%, respectively.
Conclusions: Our experience showed that early intensification
HDCT is an effective and tolerable regimen in patients relapsing
after a standard first line chemotherapy. Further clinical trials of
HDCT should analyze predictive factors for treatment outcome.
doi:10.1016/j.ejcsup.2008.06.050
TAMOXIFEN IN THE TREATMENT OF RECURRENT, ADVANCED
BORDER LINE OVARIAN CANCER: A SINGLE CENTRE EXPERIENCE
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Background: Treatment of borderline ovarian tumours is based on
surgerywhile chemotherapy is poorly effective. Advanceborder line
ovariantumoursare rarenadresponse tochemotherapy ispoor.Bor-
der line cancer frequently express estrogen receptors and few cases
responding to hormonal treatments have been reported.
Methods:Wedescribe threecasesof recurrent serousdiseaseout
of 42 newly diagnosed border line cancer observed at our institu-
tion in 5 years. In all three cases estrogen receptorwas determined
by immunohistochemistry and was found positive. Patients were
treated with 20 mg/daily tamoxifen until progression.
Results: In no case we observed a complete remission, but in all
a clinical and serological Ca 125 response was observed. In one
patient a control was maintained for 3 years. In another, after
progression, a new response was obtained doubling tamoxifen
dose. Two of 3 patients are alive continuing tamoxifen and in
response from 10 and 15 months, respectively.
Conclusions: Our data support the hypothesis that hormonal
treatment represents an option for recurrent borderline ovarian
tumours.
doi:10.1016/j.ejcsup.2008.06.051
REDISCOVERING IMMUNOTHERAPY IN COMBINATION WITH
MOLECULARLY TARGETED AGENTS IN RENAL CELL CANCER
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Renal cell carcinoma accounts for approximately 2–3% of all
malignancies and includes different histological subtypes.
Prognosis of metastatic disease (mRCC) still remains unfa-
vourable and patients survival depends on well known prognostic
factors, as defined by the MSKCC score. Overall, the median sur-
vival in advanced disease is about 14 months.
Cytokine-based immunotherapy with interferon-alfa (IFN-
alfa) and interleukin-2 (IL-2), alone or in association, is considered
the standard care for mRCC.
From 2005, in the targeted therapies era, some significant clin-
ical trials showed the promising activity and efficacy of new drugs
like Sorafenib, Sunitinib, Temsirolimus, Everolimus and Bev-
acizumab. These biomolecular agents have improved disease
control in patients with mRCC.
In particular, Sorafenib is an orally available multikinase
inhibitor that demonstrated, as single agent, an improvement of
progression-free survival in cytokine-refractory mRCC.
Some clinical trials explored the efficacy and safety of the
association between biomolecular agents such as Sorafenib itself,
Bevacizumab or Temsirolimus and immunotherapy with IFN-alfa
and IL-2.
The rationale of bio-immunotherapy of mRCC with targeted
agents in combination with cytokines is represented by their dif-
ferent mechanisms of action and possible synergistic effects in
blocking cancer growth.
The ROSORC trial is a phase II italian study of first line
therapy with Sorafenib plus low dose IL-2 administered subcu-
taneously versus Sorafenib alone in unresectable and/or meta-
static RCC. The accrual target is set at 128 patients and the
main endpoints are the progression-free survival, the overall sur-
vival, the response rate and the safety in both arms of therapy.
In our experience the association between cytokines and tar-
geted therapies is feasible and we purpose to choose this combi-
nation regimen in the upfront treatment of particular subgroups
of patients, according to risk stratification and objectives of
clinicians.
doi:10.1016/j.ejcsup.2008.06.052
IMAGE GUIDED RADIATION THERAPY (IGRT) IN THE TREAT-
MENT PLANNING OF PROSTATE CANCER: ACCURACY AND PRE-
CISION OF RADIATION THERAPY THROUGH MODERN IMAGING
TECNOLOGIES
M. Santoro, P. Petitto, D. Pingitore. Department of Onco-Hematology,
Hospital Pugliese-Ciaccio, Via Pio X, 88100 Catanzaro, Italy
The objective principal of the radiotherapy it is the control
local or locoregional to curative purpose with saving of the nor-
mal tissues. In the last decades the possibility to have available
software able to integrate diagnostic data coming from images of
Computerized Tomography (CT), of Magnetic Resonance Imag-
ing (MRI) and nuclear medicine (NM) with algorithms of calcula-
tion of doses able to calculate the dose in more dimensions have
allowed to realise the radiotherapy conformal (3D-CRT) to the
purpose to realise of radiant treatments more and more individ-
ualised and with smaller late effects.
Advances in the delivery of radiotherapy treatment such as
the 3D-CRT and Intensity Modulated Radiation Therapy (IMRT)
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